Related news from
Wed, 10 Jun 2026 16:13:51 +0000	Assessing Cencora (COR) Valuation After Kite CAR T Distribution Deal And Upcoming CFO Transition Cencora (COR) has attracted fresh attention after agreeing to support distribution of Kite’s FDA approved CAR T cell therapies, while also planning a CFO transition to Eva C. Boratto in June 2026. See our latest analysis for Cencora. Recent news around the Kite collaboration and upcoming CFO change comes as the stock price has risen 2.00% over 1 day and 7.08% over 30 days, but is still down 20.19% over 90 days. The 5 year total shareholder return of 147.29% points to a much stronger longer...
Wed, 10 Jun 2026 14:05:45 +0000	Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with...
Tue, 09 Jun 2026 15:05:00 +0000	2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
Mon, 08 Jun 2026 17:12:00 +0000	Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII A new, smaller 60 mL bottle brings pharmacy-stocking and dosing convenience to a once-daily liquid amphetamine designed for individualized titration in ADHDMONMOUTH JUNCTION, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company advancing transformative targeted CNS therapeutics, today announced the availability of DYANAVEL® XR (amphetamine) extended-release oral suspension, CII (2.5 mg/mL) in a new, smaller 60 mL bottle (NDC 24478-102-02)
Mon, 08 Jun 2026 13:55:23 +0000	Is Cencora Stock Underperforming the Nasdaq? Cencora has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Fri, 05 Jun 2026 15:30:12 +0000	Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 05 Jun 2026 13:55:02 +0000	Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wed, 03 Jun 2026 11:05:38 +0000	Is McKesson Stock Underperforming the Dow? McKesson has underperformed the Dow over the past year, but analysts are highly optimistic about the stock’s prospects.
Tue, 02 Jun 2026 12:00:00 +0000	Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies CONSHOHOCKEN, Pa., June 02, 2026--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel).
Mon, 01 Jun 2026 23:11:42 +0000	Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)? Cencora has appointed Eva C. Boratto as Executive Vice President and Chief Financial Officer effective June 29, 2026, announced a share repurchase program of up to US$2.00 billion, and is facing a new California labor class action lawsuit. The combination of a seasoned healthcare-focused finance leader joining the company and a very large buyback authorization creates an important moment for reassessing Cencora’s capital allocation and governance profile. We’ll now examine how the...
Mon, 01 Jun 2026 18:39:18 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
Mon, 01 Jun 2026 07:00:00 +0000	LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
Wed, 27 May 2026 11:14:26 +0000	Cencora nabs ex-CVS exec as new CFO Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
Wed, 27 May 2026 10:55:00 +0000	Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer CONSHOHOCKEN, Pa., May 27, 2026--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition.
Thu, 21 May 2026 20:30:00 +0000	Cencora Announces Updated Fiscal Year 2026 Financial Outlook CONSHOHOCKEN, Pa., May 21, 2026--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company’s previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end of
Tue, 19 May 2026 05:32:55 +0000	3 Market-Beating Stocks to Research Further The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Mon, 18 May 2026 12:36:45 +0000	Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]
Sun, 17 May 2026 21:13:37 +0000	Cencora Legal Probes Test Investor Confidence After Weaker Q2 Revenue Outlook Multiple law firms have launched investigations into Cencora (NYSE:COR) for potential securities law violations following its Q2 2026 results. The company reported revenue that missed prior estimates and reduced its revenue growth forecast, prompting the legal scrutiny. The investigations focus on whether Cencora and its management misled investors around the period of the reported results and updated outlook. Cencora, trading at $257.71 at the last close, is now under a spotlight that goes...
Sat, 16 May 2026 21:56:55 +0000	The Top 5 Analyst Questions From Cencora’s Q1 Earnings Call Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors behind the underperformance, including faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, impacts from recent manufacturer price reductions, and lingering effects from the loss of certain customers. CEO Robert Mauch emphasized the resilience of Cencora’s business model, noting ongoing growth in spec
Fri, 15 May 2026 13:25:03 +0000	Wells Fargo Maintains Overweight Rating on Cencora (COR) Cencora, Inc. (NYSE:COR) is one of the 10 Best Depressed Stocks to Buy in 2026. On May 11, 2026, Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora, Inc. (NYSE:COR) to $331 from $429 while maintaining an Overweight rating on the shares. The firm said the magnitude of the slowdown in U.S. […]

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!